Kornimate/medical-research-clean huggingface dataset:
treatments for covid-19: canadian arm of the solidarity trial

Conditions: COVID-19

Summary: this study is an adaptive, randomized, open-label, controlled clinical trial, in collaboration with countries around the world through the world health organization.

subjects will be randomized, across one, two, three or up to four separate randomizations, to receive either standard-of-care products or the study medication plus standard of care, while being hospitalized for covid-19. randomization who: imatinib vs infliximab vs artesunate vs standard of care randomization dex: dexamethasone vs standard of care randomization lsalt: lsalt peptide vs standard of care hospitalized subjects will require blood sampling for screening and on days 1 and 5.

Eligibility criteria:
inclusion criteria: each participant must meet all of the following inclusion criteria to participate in this study: 1. ≥ 18 years of age 2. has laboratory-confirmed sars-cov-2 infection as determined by pcr, or other commercial or public health assay in any specimen, within 14 days prior to randomization. 3. hospitalized at a participating centre 4. primary reason for hospitalization or subsequent in-hospital illness is because of acute covid19 infection 5. first admission for acute covid19 in addition, there will be the below intervention-specific inclusion: randomization who will have no other specific inclusion criteria. randomization lsalt will have no other specific inclusion criteria. randomization dex will have the following specific inclusion criteria 1. on 10 days of steroid course and 2. receiving any supplemental oxygen for 10 days exclusion criteria: all participants meeting any of the following exclusion criteria at baseline will be excluded from participation in this study: 1. anticipated transfer to another hospital, within 72 hours, which is not a study site 2. expected to not survive beyond 24 hours 3. receiving one of the study drugs at time of enrolment in addition, there will be the below intervention-specific exclusions: randomization who: these will be drug-specific exclusions; patients will still be eligible for randomization in randomization who to the other available study drugs (in randomization who or subsequent randomizations). artesunate: 1. known hypersensitivity to artesunate imatinib: 1. pregnant or breastfeeding; 2. known hypersensitivity to imatinib; 3. liver transaminases (either alt or ast) \> 5x upper limit of normal infliximab: 1. known moderate or severe heart failure, per treating clinician, defined as new york heart association (nyha) class iii or iv 2. known or suspected active tuberculosis 3. known hypersensitivity to infliximab randomization lsalt: 1. known hypersensitivity or prior use of lsalt peptide. 2. pregnant or breastfeeding randomization dex: 1. receiving glucocorticoids for a specific, non-covid-19 indication

Keywords: artesunate infliximab imatinib dexamethasone sars-cov-2 lsalt peptide
development of a motivational intervention to improve treatment adherence in ms

Conditions: Relapsing-remitting Multiple Sclerosis

Summary: as many as 50% of ms patients prematurely discontinue their disease modifying medications. for this study, we will develop a telephone-based talk therapy intervention and then conduct a randomized controlled trial. patients will be assigned to either 5 weekly 20 minute telephone sessions of psychotherapy or a brief education control condition. we hypothesize that patients undergoing phone therapy will be more likely to indicate they are interested in resuming taking disease modifying medications than patients given brief education and treatment as usual.


Eligibility criteria:
inclusion criteria: * diagnosis of relapsing remitting ms based on established guidelines * previously discontinued recommended therapy * provider recommendation for dmt re-initiation * at least 18 years of age * access to a telephone * english speaking exclusion criteria: * diagnosis other than relapsing remitting ms * provider does not recommend dmt re-initiation * pregnant or breastfeeding (females)

Keywords: multiple sclerosis disease modifying medication relapsing-remitting ms motivational interviewing telephone counseling
clinical assessment of the effectiveness and safety of herpes patch sos in the treatment of herpes simplex labialis in comparison to a competitor's product.

Conditions: Herpes Simplex Labialis

Summary: recent clinical studies showed, that a hydrocolloid patch is effective, well tolerated and comparable with aciclovir cream 5 % for the treatment of hsl lesions, while affording additional benefits of wound protection, discretion and relief of social embarrassment. the aim of the actual study was the clinical assessment of the effectiveness and safety of hansaplast® sos herpes patch (hphp) in comparison to compeed® herpes vesicle patch (chp) in treating hsl. both products are ce-certificated and are available at the market for medical devices.


Eligibility criteria:
inclusion criteria: * at least 18 years old * with a history of recurrent hsl of the lips and/or perioral skin * lesions typically manifesting as classical lesions * duration of hsl symptoms not more than three days * haven´t used acyclovir or other cold sore therapies exclusion criteria: * pregnancy * lactating women * women of child-bearing age without medically secured contraceptions * topical or systemic therapy with analgesic * anti-inflammatory or antiviral agents within the last 2 weeks * topical therapy within the treatment area * systemic therapy with cytostatics or immunosuppressants

Keywords: hsl of lips perioral skin duration of hsl symptoms not more than three days not acyclovir or other cold sore therapies
correlation of angle kappa , corneal high order aberrations and total eye aberrations in various refractive errors

Conditions: Aberration, Corneal Wavefront

Summary: identification of the correlation between angle kappa , corneal high order aberrations and total eye aberrations in myopic hyperopic and astigmatic patients

the patient will be thoroughly examined clinically on slit lamp detailed history will be obtained visual acuity will be measured and patient refraction will be taken then imaging on sirius topographer will be used to obtain angle kappa and high order aberrations of the cornea and i-design pentacam imaging will be used to get the total aberrations of the eye

Eligibility criteria:
inclusion criteria: 1. patients with errors of refraction above the age of 18 2. no history of trauma. 3. no other ocular disease . exclusion criteria: 1. patient under age of 18 2. patients with systemic disease. 3. patient with corneal diseases 4. patient who did any sort of occular surgery 5. patient refusal
head motion in pediatric patients endotracheally intubated with video laryngoscopy versus direct laryngoscopy

Conditions: Intubation; Difficult; Cervical Spine Injury

Summary: the purpose of this study is to evaluate if intubation with video laryngoscopy (vl) will result in less head motion and therefore less cervical motion when compared with direct laryngoscopy (dl). the aim of the study is to determine the amount of head motion (extension, flexion and rotation) when using storz c-mac® video laryngoscopes and direct laryngoscopes. secondarily, the study will also measure the number of attempts to properly intubate and the time required for intubation with either technique.

investigator initiated single site prospective and randomized controlled trial.

Eligibility criteria:
inclusion criteria: * patients being orally intubated in the operating room as per standard anesthesia procedures exclusion criteria: * previous history of cervical spine injury or surgery * craniofacial abnormalities * airway congenital abnormalities * airway prior to surgery

Keywords: storz c-mac® pediatric airway cervical spine injury trauma airway management
a post-market study of bandgrip in traumatic wound closure compared to suture

Conditions: Laceration of Skin

Summary: an unbalanced (2:1) randomized study comparing two methods of traumatic skin closure in an er setting: bandgrip vs suture

up to 45 subjects at up to 2 study sites who present to the er for treatment of a skin laceration will be consented and randomized to treatment with suture or bandgrip. subjects will be followed for 30 days post treatment to assess cosmetic quality of wound healing, evidence of adverse events related to closure method, and speed and completeness of wound closure and removal of closure devices.

Eligibility criteria:
inclusion criteria: * male/female age 18-65. * subject presents to emergency room with at least one skin laceration that is assessed as requiring a suture closure on the trunk or extremities (excluding hands and feet). * the length of the laceration is less than or equal to 1.5 inches. * subject is otherwise in good general health in the opinion of the investigator. * subject must be willing to follow instructions for wound care provided by investigator and refrain from picking at the treatment device, applying topical medications to the wound, and swimming or soaking in a tub until bandgrip or the sutures are removed. * subject agrees to return for follow-up evaluations. * subject (or guardian) is able to comprehend and give informed consent for participation in this study. exclusion criteria: * significant multiple trauma (merely multiple wounds are allowed). * the wound involves a lower limb with critical limb ischemia. * concurrent acute infection requiring intravenous or oral antibiotics. * bleeding, coagulation and or clotting disorders. * subject is on dialysis. * inflammatory and or allergic diseases or conditions of the skin: for example, psoriasis, eczema or dermatitis. * history of drug abuse. * chronic use of oral steroids or immunosuppressants. * known personal or family history of keloid or hypertrophic scarring. * history of abnormal wound healing. * burst stellate lacerations due to a crush or hard blow. * animal or human bite or scratch. * wound is in the head, hands or feet or in a high skin tension area or across an area of increased skin tension on a joint. * investigator objects to a patient's involvement in the study protocol. * known allergy to components to bandgrip or suture material. * known cognitive or psychiatric disorder. * wound requiring debridement of devitalized or contaminated tissue. * wound at site of active rash/skin lesion making evaluation difficult. * previously treated wound or has failed to heal. * puncture wound.
impact of sarcopenia on dyspnea in patients with asthma

Conditions: Sarcopenia; Asthma; Dyspnea; Dyspnea; Asthmatic; Cytokines; Adipokines; Myokine; Muscle Disorder

Summary: dyspnea in asthma, is mainly due to airway obstruction but can be caused by several alternative diagnoses. the impact of sarcopenia on dyspnea in patients with asthma is unknown. sarcopenic asthma had a reduced physical activity and is associated with airway obstruction compared to non-sarcopenic asthma. in patients with obstructive pulmonary disease, sarcopenia is associated with shallow breathing and diverse sensory and affective components of exertional dyspnea . the morbidity of sarcopenia is also increased by systemic inflammation and the production of inflammatory cytokines as found in inflammatory airway obstruction. the investigators will investigate the prevalence and impact of sarcopenia in asthmatics patients. this will enable to better manage sarcopenia in asthmatic patients, understand its origins and personalize treatment.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * patient affiliated to a social security scheme. * patient capable of giving free, informed, written and signed consent. * asthmatic patients with a diagnosis made by a pulmonologist on gina level 4 or 5 treatment * act asthma control score \< 20 * patient judged by the investigator to be able to to perform a maximal exercise test. exclusion criteria: * patient under guardianship/trusteeship/supervision of justice * pregnant or breast-feeding women * unstable heart disease * patients who have been smoking or have stopped smoking for less than 5 years,

Keywords: asthma sarcopenia dyspnea
phase 3 efficacy and safety study of peginterferon lambda-1a and ribavirin with telaprevir

Conditions: Hepatitis C Virus

Summary: the purpose of this study is to determine whether peginterferon lambda-1a (lambda) combined with ribavirin (rbv) and telaprevir (tvr) is effective in the treatment of chronic hepatitis c (chc) compared to peginterferon alfa-2a (alfa-2a) combined with rbv and telaprevir.


Eligibility criteria:
for more information regarding bms clinical trial participation, please visit www.bmsstudyconnect.com. inclusion criteria: * chronic hepatitis c genotype 1. gt-1b capped at 50 % of naïve subjects * naives to prior anti-hcv therapy \[interferon (ifn) and direct antiviral agent (daa) based\] * relapsers (defined as subjects who had undetectable hcv ribonucleic acid (rna) on prior treatment regimen of alfa-2a/rbv and hepatitis c virus (hcv) rna \> 25iu/ml after discontinuation of treatment). capped at 20% * hcv rna ≥ 100,000 iu/ml * subjects with compensated cirrhosis can be enrolled and will be capped at approximately 10% * seronegative for human immunodeficiency virus (hiv) and hepatitis b surface antigen (hbsag) * men or women, 18-70 years of age exclusion criteria: * chronic liver disease due to causes other than chronic hcv * current or past evidence of decompensation * conditions that preclude the use of alfa/rbv/tvr per respective labels * diagnosed or suspected hepatocellular carcinoma
dair for infected total hip arthroplasty - does the operative approach influence the functional result?

Conditions: Hip Prosthesis Infection; Arthroplasty Complications

Summary: the functional outcome and quality of life after treatment for an infected hip arthroplasty have been found to be significantly worse compared to an uncomplicated arthroplasty. however, the type of revision surgery chosen to treat the infection plays a role for the functional outcome. the concept of dair (debridement, antibiotics and implant retention) has been shown to yield god results with respect to infection control in cases of early infection with a stable implant and better functional results than a to-stage revision. in patients where infection control was achieved after just one dair procedure the functional outcome was comparable to an uncomplicated primary arthroplasty. however, it is not known if the operative approach used for the primary and revision surgery plays a role for the functional result after treatment of an infected total hip arthroplasty with dair. the project's aim is to investigate if the choice of the operative approach (transgluteal or posterior) for the primary hip replacement and the revision surgery has an influence on the functional result after debridement and implant retention for an infected total hip replacement.

potential study participants will be identified in the norwegian arthroplasty register. patients who have been revised once for an infected total hip arthroplasty with debridement and implant retention and in whom either the transgluteal og posterior operative approach was used in both procedures will be selected. the potential participants will be contacted by letter. they will be asked for written informed consent and to fill out three questionnaires: the hip disability osteoarthritis score (hoos), which also allows for the calculation of the western ontario and mcmaster universities osteoarthritis index (womac), the eq-5d (quality of life) and a questionnaire asking about confirmation that the patient only has been revised once for his/her infected arthroplasty, about limping, other complications (nerve injury, dislocation, reoperation for other causes than infection), if the infection is considered to have been eradicated and overall satisfaction. the data recorded in the norwegian arthroplasty register will be used in a multiple linear regression analysis to evaluate if the surgical approach is an independent factor influencing the outcome measures.

Eligibility criteria:
inclusion criteria: * the infected total hip arthroplasty has only been revised once. * the revision procedure was a debridement and implant retention. * both, the primary and the revision procedure were performed through the same surgical approach; either the transgluteal or the posterior approach. exclusion criteria: * no written informed consent.

Keywords: dair transgluteal approach posterior approach
optimal pediatric heart transplant immunosuppression with micrornas (optima)

Conditions: Cardiac Failure; Graft Rejection

Summary: this study aims to discover circulating micrornas (associated with drug doses and levels) that can be used to characterize the overall immune state in pediatric heart transplant patients and predict patients that will go on to develop infection and rejection. micrornas (mirs) are small, non-coding rna molecules that regulate gene expression and serve as molecular biomarkers found in the circulation.

the study objectives will be accomplished in a prospective, multicenter observational, longitudinal cohort study that includes 100-150 pediatric heart transplant (pht) patients from the united states. patients will be screened for eligibility and enrolled \~1 month after pht. study participation will last 24 months. all patients will follow the center's standard of care surveillance schedule after transplant. blood samples will be collected for mir evaluation at: 1. specified time intervals after transplant and 2. when a clinical event of interest occurs, including rejection, infection, or major change in immunosuppression. research samples will be collected and used to evaluate microrna expression as well as other biomarkers related to heart transplantation and immunosuppression medications. additional data collection will include demographics, medical history, medications, human leukocyte (hla)/donor specific antibody (dsa) evaluations, endomyocardial biopsy (emb), echocardiography, donor-derived cell-free dna (dd-cfdna), and other post-transplant events and testing. this work will form the basis for a non-invasive, genomic blood test that can be used to monitor patients after heart transplant to mitigate complications of over-immunosuppression, such as infection, without increasing the risks of under-immunosuppression, such as rejection.

Eligibility criteria:
inclusion criteria: * age ≤ 18 years at enrollment * receipt of orthotopic heart transplant (oht) within the prior 1 month ± 2 weeks * planned follow-up at the transplant center for a minimum of one-year. * caregiver able and willing to comply with the study visit schedule, study procedures, and study requirements. exclusion criteria: * recipient of a multi-organ transplant * history of prior solid organ transplant before the index heart transplant * ongoing mechanical circulatory support or hemodynamic instability * active infection requiring either a) hospitalization b) treatment with antimicrobial therapy or c) reduction in immunosuppression * history of rejection prior to enrollment * inability to collect specified blood volume at enrollment +/- 1 week
laser therapy on controlling pain during orthondontic treatment

Conditions: Malocclusion

Summary: to evaluate the effectiveness of pain reduction on a initial orthodontic treatment by using 810nm diode laser compared to a placebo. methods: this study will include two parallels groups, 30 adult patients each (mean age 18 - 40) that will be asked to fill a questionnaire related with pain before starting orthodontic treatment with tip edge technique. patients from one of the groups will receive laser therapy on both upper and lower maxillary according to the protocol. the patients from the other group will receive a placebo simulating a laser therapy on both maxillary. after the process, both groups will be checked on different times (12hrs-24hrs-48hrs-72hrs after) by filling a questionnaire related with pain each time.

this is a parallel, double-blind, controlled, single-center clinical trial conducted in systemically healthy subjects requiring orthodontic treatment without extractions at the start of treatment in bogotá, colombia. sixty patients (60) will be randomized in a 1: 1 ratio, to either of the two arms of this trial. this study will consist of a single visit by the patient, in this visit the assembly and activation of the upper and lower orthodontic appliances will be carried out. measurements of the primary outcome variable will be done remotely through a virtual pain monitoring questionnaire through a visual analog scale (baseline, 12 hours, 24 hours, 48 hours, 72 hours). after screening a computer-generated scrambling code will be used for allocation in blocks of 6 to the two treatments. the identity of included patients will not be provided to the trial team, in order to preserve the blinded aspect of the trial. the identity of the research treatment associated with each randomization number will be hidden from the trial team and patients. the final analysis is scheduled for when 100% of the patients (60 subjects) reach the 72-hour evaluation.

Eligibility criteria:
inclusion criteria: * subjects must have signed and dated an informed consent form approved by the irb in accordance with regulatory and institutional guidelines. this form must be obtained before performing any procedure related to the protocol that is not part of the subject's normal regimen. * no need extractions * no need stripping exclusion criteria: * periodontal disease * pregnant or lactance * medicated patients (analgesic, anti-inflammatory drugs, systemic corticosteroids, and calcium channel blockers) * cardiac markpaser

Keywords: laser orthodontic tip edge